Dexamethasone Treatment Options

A collection of 1465 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.

Home

All Treatments

Dexamethasone

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

NCT03834506

Completed

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC but have progressed on or are intolerant to Next Generation Hormonal Agent (NHA). There are two primary study hypotheses. Hypothesis 1: The combination of pembrolizumab plus docetaxel plus prednisone is superior to placebo plus docetaxel plus pr... Read More

Gender:

MALE

Ages:

18 years and above

Trial Updated:

07/08/2025

Locations: University of South Alabama, Mitchell Cancer Institute ( Site 0065), Mobile, Alabama +214 locations

University of South Alabama, Mitchell Cancer Institute ( Site 0065), Mobile, Alabama

St. Joseph Heritage Healthcare ( Site 0069), Fullerton, California

University of Southern California Norris Comprehensive Cancer Center ( Site 0061), Los Angeles, California

USC Norris Oncology Hematology Newport Beach ( Site 0093), Newport Beach, California

University of California San Francisco ( Site 0023), San Francisco, California

University of Colorado Cancer Center ( Site 0022), Aurora, Colorado

Yale Cancer Center ( Site 0038), New Haven, Connecticut

Moffitt Cancer Center ( Site 0080), Tampa, Florida

Georgia Cancer Center at Augusta University ( Site 0026), Augusta, Georgia

Mount Sinai Hospital Medical Center ( Site 0042), Chicago, Illinois

Methodist Hospital- Merriillville ( Site 0008), Merrillville, Indiana

Karmanos Cancer Institute ( Site 0077), Detroit, Michigan

Henry Ford Health System ( Site 0039), Detroit, Michigan

Cancer & Hematology Centers of Western Michigan ( Site 0013), Grand Rapids, Michigan

Washington University School of Medicine ( Site 0057), Saint Louis, Missouri

St. Vincent Frontier Cancer Center ( Site 0016), Billings, Montana

Nebraska Cancer Specialists ( Site 0034), Omaha, Nebraska

Comprehensive Cancer Centers of Nevada ( Site 0092), Las Vegas, Nevada

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0004), Hackensack, New Jersey

Associated Medical Professionals of NY ( Site 0060), Syracuse, New York

Duke Cancer Center ( Site 0010), Durham, North Carolina

W. G. Bill Hefner VA Medical Center ( Site 0029), Salisbury, North Carolina

University Hospitals Cleveland Medical Center ( Site 0036), Cleveland, Ohio

Oregon Health Sciences University ( Site 0031), Portland, Oregon

Carolina Urologic Research Center ( Site 0070), Myrtle Beach, South Carolina

Inova Schar Cancer Institute ( Site 0006), Fairfax, Virginia

Virginia Cancer Institute ( Site 0052), Richmond, Virginia

Blue Ridge Cancer Care ( Site 0086), Roanoke, Virginia

Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013), Berazategui, Buenos Aires

Instituto de Investigaciones Clinicas ( Site 1000), Mar del Plata, Buenos Aires

Centro de Diagnostico Urologico ( Site 1008), Buenos Aires, Caba

Hospital Britanico de Buenos Aires ( Site 1006), Buenos Aires, Caba

Sanatorio Parque ( Site 1002), Rosario, Santa Fe

Instituto de Investigaciones Metabolicas [Buenos Aires, Argentina] ( Site 1011), Buenos Aires, Not set

Hospital Aleman ( Site 1004), Buenos Aires, Not set

Instituto Medico Alexander Fleming ( Site 1010), Buenos Aires, Not set

CEMAIC ( Site 1014), Cordoba, Not set

St George Hospital ( Site 0157), Kogarah, New South Wales

Macquarie University ( Site 0151), Macquarie University, New South Wales

Port Macquarie Base Hospital ( Site 0153), Port Macquarie, New South Wales

Calvary Mater Newcastle ( Site 0148), Waratah, New South Wales

Redcliffe Hospital ( Site 0161), Redcliffe, Queensland

John Flynn Hospital & Medical Centre ( Site 0164), Tugun, Queensland

Hollywood Private Hospital ( Site 0163), Nedlands, Western Australia

Ordensklinikum Linz GmbH Elisabethinen ( Site 0373), Linz, Oberosterreich

Medizinische Universitat Graz ( Site 0374), Graz, Steiermark

SCRI-CCCIT GesmbH ( Site 0371), Salzburg, Not set

Medizinische Universitaet Wien ( Site 0375), Wien, Not set

Hospital de Caridade de Ijui ( Site 1038), Ijui, Rio Grande Do Sul

Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1021), Porto Alegre, Rio Grande Do Sul

Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 1035), Itajai, Santa Catarina

Hospital de Base de Sao Jose de Rio Preto ( Site 1022), Sao Jose do Rio Preto, Sao Paulo

A.C. Camargo Cancer Center ( Site 1026), Sao Paulo, Not set

Nova Scotia Health Authority QEII-HSC ( Site 0114), Halifax, Nova Scotia

Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0116), Hamilton, Ontario

Grand River Hospital ( Site 0120), Kitchener, Ontario

Lakeridge Health ( Site 0117), Oshawa, Ontario

Sunnybrook Research Institute ( Site 0108), Toronto, Ontario

Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario

CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102), Rimouski, Quebec

CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105), Sherbrooke, Quebec

CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0103), Quebec, Not set

Centro Investigación del Cáncer James Lind ( Site 1041), Temuco, Araucania

Rey y Oreilly Limitada ( Site 1048), Temuco, Araucania

Fundacion Arturo Lopez Perez ( Site 1049), Santiago, Region M. De Santiago

Pontificia Universidad Catolica de Chile ( Site 1047), Santiago, Region M. De Santiago

Bradford Hill Centro de Investigaciones Clinicas ( Site 1044), Santiago, Region M. De Santiago

Centro de Investigaciones Clinicas Vina del Mar ( Site 1042), Vina del Mar, Valparaiso

Peking University First Hospital ( Site 1303), Beijing, Beijing

The Fifth Medical Center of PLA General Hospital ( Site 1307), Beijing, Beijing

Beijing Cancer Hospital ( Site 1305), Beijing, Beijing

The First Affiliated Hospital of Xiamen University ( Site 1319), Xiamen, Fujian

Sun Yat Sen Memorial Hospital ( Site 1323), Guangzhou, Guangdong

The First Affiliated Hospital of Guangzhou Medical University ( Site 1330), Guangzhou, Guangdong

Harbin Medical University Cancer Hospital ( Site 1326), Harbin, Heilongjiang

Henan Cancer Hospital ( Site 1321), Zhengzhou, Henan

Hubei Cancer Hospital ( Site 1329), Wuhan, Hubei

Hunan Cancer Hospital ( Site 1320), Changsha, Hunan

Nanjing Drum Tower Hospital ( Site 1312), Nanjing, Jiangsu

Fudan University Shanghai Cancer Center ( Site 1300), Shanghai, Shanghai

Zhongshan Hospital Fudan University ( Site 1301), Shanghai, Shanghai

The Second Affiliated Hospital of Zhejiang University School of Medicine ( Site 1309), Hangzhou, Zhejiang

Zhejiang Provincial People's Hospital ( Site 1310), Hangzhou, Zhejiang

Hospital Pablo Tobon Uribe ( Site 1066), Medellin, Antioquia

Biomelab S A S ( Site 1067), Barranquilla, Atlantico

Clinica de la Costa Ltda. ( Site 1073), Barranquilla, Atlantico

Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1068), Valledupar, Cesar

Oncomedica S.A. ( Site 1057), Monteria, Cordoba

Instituto Nacional de Cancerologia E.S.E ( Site 1061), Bogota, Distrito Capital De Bogota

Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1062), Bogota, Distrito Capital De Bogota

Oncologos del Occidente S.A. ( Site 1072), Pereira, Risaralda

Centro Medico Imbanaco de Cali S.A ( Site 1064), Cali, Valle Del Cauca

Hemato Oncologos S.A. ( Site 1065), Cali, Valle Del Cauca

C.H. de Saint Quentin ( Site 0481), Saint Quentin, Aisne

Clinique Sainte Anne ( Site 0431), Strasbourg, Alsace

Centre Jean Perrin ( Site 0434), Clermont-Ferrand, Auvergne

Centre Leon Berard ( Site 0422), Lyon, Auvergne

Institut Paoli Calmettes. ( Site 0419), Marseille, Bouches-du-Rhone

CHU Jean Minjoz ( Site 0423), Besancon, Doubs

CHU de Brest -Site Hopital Morvan ( Site 0441), Brest, Finistere

Institut Bergonie ( Site 0421), Bordeaux, Gironde

Institut Claudius Regaud IUCT Oncopole ( Site 0418), Toulouse, Haute-Garonne

Hopital Foch ( Site 0428), Suresnes, Hauts-de-Seine

Institut De Cancerologie De L Ouest ( Site 0448), Saint Herblain, Loire-Atlantique

Centre Hospitalier Regional du Orleans ( Site 0430), Orleans, Loiret

Centre D Oncologie de Gentilly ( Site 0432), Nancy, Meurthe-et-Moselle

C.H.U. Lyon Sud ( Site 0436), Pierre Benite, Rhone

CHU Amiens Picardie Site Sud Amiens ( Site 0438), Amiens, Somme

Institut Gustave Roussy ( Site 0416), Villejuif, Val-de-Marne

Institut Sainte Catherine ( Site 0447), Avignon, Vaucluse

Institut Mutualiste Montsouris ( Site 0446), Paris, Not set

Universitaetsklinikum Freiburg - Medizinische Klinik ( Site 0304), Freiburg, Baden-Wurttemberg

Universitaetsklinikum in Mannheim ( Site 0314), Mannheim, Baden-Wurttemberg

Studienpraxis Urologie ( Site 0309), Nuertingen, Baden-Wurttemberg

Universitaetsklinik fuer Urologie ( Site 0307), Tuebingen, Baden-Wurttemberg

Klinikum Rechts der Isar ( Site 0300), Muenchen, Bayern

Universitaetsklinik der Paracelsus Medizinischen Privatuniversitaet ( Site 0318), Nuernberg, Bayern

Universitaetsklinikum Wuerzburg ( Site 0302), Wuerzburg, Bayern

Universitaetsklinikum Goettingen ( Site 0345), Goettingen, Niedersachsen

Uniklinik RWTH Aachen ( Site 0308), Aachen, Nordrhein-Westfalen

Universitaetsklinikum des Saarlandes ( Site 0348), Homburg, Saarland

Universitaetsklinikum Jena ( Site 0305), Jena, Thuringen

Charite Universitaetsmedizin Berlin ( Site 0301), Berlin, Not set

Cork University Hospital ( Site 0727), Cork, Not set

Tallaght University Hospital ( Site 0730), Dublin, Not set

Mid Western Cancer Centre ( Site 0728), Limerick, Not set

Soroka Medical Center ( Site 0548), Beer Sheva, Not set

Assaf Harofeh MC ( Site 0547), Beer Yaakov-Zerifin, Not set

Rambam Medical Center ( Site 0543), Haifa, Not set

Hadassah Ein Kerem Medical Center ( Site 0546), Jerusalem, Not set

Meir Medical Center ( Site 0544), Kfar Saba, Not set

Rabin Medical Center ( Site 0545), Petach-Tikwa, Not set

Chaim Sheba Medical Center ( Site 0541), Ramat Gan, Not set

Sourasky Medical Center ( Site 0542), Tel Aviv, Not set

Istituto Clinico Humanitas Research Hospital ( Site 0452), Rozzano, Milano

Azienda Ospedaliera Cannizzaro ( Site 0458), Catania, Not set

A.O. Universitaria di Modena ( Site 0454), Modena, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0457), Napoli, Not set

Azienda Ospedaliera San Camillo Forlanini ( Site 0455), Roma, Not set

Azienda Ospedaliera Santa Maria Terni ( Site 0456), Terni, Not set

Presidio Ospedaliero Santa Chiara ( Site 0451), Trento, Not set

National Cancer Center Hospital East ( Site 0702), Kashiwa, Chiba

Toho University Sakura Medical Center ( Site 0703), Sakura, Chiba

National Hospital Organization Shikoku Cancer Center ( Site 0716), Matsuyama, Ehime

Kanazawa University Hospital ( Site 0701), Kanazawa, Ishikawa

Kitasato University Hospital ( Site 0705), Sagamihara, Kanagawa

Yokohama City University Medical Center ( Site 0706), Yokohama, Kanagawa

Nara Medical University Hospital ( Site 0715), Kashihara, Nara

Kindai University Hospital ( Site 0714), Osakasayama, Osaka

Osaka University Hospital ( Site 0713), Suita, Osaka

Saitama Medical University International Medical Center ( Site 0708), Hidaka, Saitama

Dokkyo Medical University Saitama Medical Center ( Site 0707), Koshigaya, Saitama

Hamamatsu University Hospital ( Site 0720), Hamamatsu, Shizuoka

Yamaguchi University Hospital ( Site 0717), Ube, Yamaguchi

Chiba Cancer Center ( Site 0704), Chiba, Not set

Kyushu University Hospital ( Site 0718), Fukuoka, Not set

University of Miyazaki Hospital ( Site 0721), Miyazaki, Not set

Nagasaki University Hospital ( Site 0719), Nagasaki, Not set

Toranomon Hospital ( Site 0711), Tokyo, Not set

Nippon Medical School Hospital ( Site 0709), Tokyo, Not set

Keio University Hospital ( Site 0710), Tokyo, Not set

National Cancer Center ( Site 0174), Goyang-si, Kyonggi-do

Seoul National University Bundang Hospital ( Site 0175), Seongnam-si, Kyonggi-do

Seoul National University Hospital ( Site 0171), Seoul, Not set

Asan Medical Center ( Site 0176), Seoul, Not set

Samsung Medical Center ( Site 0172), Seoul, Not set

Medisch Centrum Leeuwarden ( Site 0477), Leeuwarden, Fryslan

Ziekenhuis Gelderse Vallei ( Site 0485), Ede, Gelderland

Radboud University Medical Center ( Site 0470), Nijmegen, Gelderland

VieCuri Medisch Centrum ( Site 0487), Venlo, Limburg

Jeroen Bosch Ziekenhuis ( Site 1200), Den Bosch, Noord-Brabant

Catharina Ziekenhuis ( Site 0472), Eindhoven, Noord-Brabant

Antoni van Leeuwenhoek Ziekenhuis ( Site 0480), Amsterdam, Noord-Holland

Ziekenhuis Hilversum ( Site 0466), Hilversum, Noord-Holland

Ziekenhuisgroep Twente ( Site 0469), Hengelo, Overijssel

Reinier de Graaf Groep ( Site 0484), Delft, Zuid-Holland

Hagaziekenhuis ( Site 1201), Den Haag, Zuid-Holland

Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565), Chelyabinsk, Chelyabinskaya Oblast

Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0585), Krasnoyarsk, Krasnoyarskiy Kray

SBIH City clinical hospital named after D.D. Pletniov ( Site 0575), Moscow, Moskva

Russian Scientific Center of Radiology ( Site 0559), Moscow, Moskva

Central Clinical Hospital with Polyclinic ( Site 0562), Moscow, Moskva

National Medical Research Radiological Center ( Site 0556), Moscow, Moskva

Volga District Medical Center Federal Medical and Biological Agency ( Site 0572), Nizhny Novgorod, Nizhegorodskaya Oblast

Omsk Clinical Oncology Dispensary ( Site 0568), Omsk, Omskaya Oblast

SBHI Samara Regional Clinical Oncology Dispensary ( Site 0576), Samara, Samarskaya Oblast

Clinical Research Center of specialized types medical care-Oncology ( Site 0570), Saint Petersburg, Sankt-Peterburg

Russian Scientific Center of Radiology and Surgical Technologies ( Site 0567), Saint Petersburg, Sankt-Peterburg

SPb SBHI City Clinical Oncological Dispensary ( Site 0571), Saint Petersburg, Sankt-Peterburg

Leningrad Regional Oncology Center ( Site 0588), Saint-Petersburg, Sankt-Peterburg

Tomsk National Research Medical Center of Russian Academy of Sciences ( Site 0579), Tomsk, Tomskaya Oblast

Instituto Catalan de Oncologia - ICO ( Site 0330), L Hospitalet De Llobregat, Barcelona

Hospital Consorci Sanitari Parc Tauli ( Site 0335), Sabadell, Barcelona

Hospital Universitario Marques de Valdecilla ( Site 0336), Santander, Cantabria

Hospital Josep Trueta ( Site 0321), Girona, Gerona

Hospital del Mar ( Site 0333), Barcelona, Not set

Hospital Clinic ( Site 0323), Barcelona, Not set

Hospital Universitario Ramon y Cajal ( Site 0328), Madrid, Not set

Hospital Clinico San Carlos ( Site 0324), Madrid, Not set

Hospital Universitario HM Sanchinarro ( Site 0322), Madrid, Not set

Hospital Universitario Virgen de la Victoria ( Site 0337), Malaga, Not set

Hospital Virgen del Rocio ( Site 0329), Sevilla, Not set

National Cheng Kung University Hospital ( Site 0134), Tainen, Tainan

China Medical University Hospital ( Site 0132), Taichung, Not set

Taichung Veterans General Hospital ( Site 0133), Taichung, Not set

National Taiwan University Hospital ( Site 0131), Taipei, Not set

Taipei Veterans General Hospital ( Site 0135), Taipei, Not set

University Hospitals Bristol NHS Foundation Trust ( Site 0530), Bristol, Bristol, City Of

Cambridge University Hospitals NHS Trust ( Site 0540), Cambridge, Cambridgeshire

Torbay Hospital ( Site 0532), Torquay, Devon

Weston Park Hospital ( Site 0539), Sheffield, England

Royal Marsden Hospital ( Site 0526), Sutton, England

Mount Vernon Cancer Centre ( Site 0536), Northwood, Hertfordshire

Barts Cancer Institute ( Site 0483), London, London, City Of

University of North Midlands NHS Foundation Trust ( Site 0527), Stoke-on-Trent, Staffordshire

Conditions: Prostatic Neoplasms

Learn More ›

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568

Active Not Recruiting

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/08/2025

Locations: City of Hope, Duarte, California +27 locations

City of Hope, Duarte, California

City of Hope - Lennar Foundation Cancer Center, Irvine, California

Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado

Karmanos Cancer Institute., Detroit, Michigan

Washington University School of Medicine, Saint Louis, Missouri

Peter MacCallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Cross Cancer Institute, Edmonton, Alberta

Hamilton Health Sciences, Hamilton, Ontario

University Health Network, Toronto, Ontario

Fakultni Nemocnice Ostrava, Ostrava, Not set

Rigshospitalet, København Ø, Not set

Hôpital Saint-Louis, Paris, Not set

CHU de Poitiers - La Miletrie, Poitiers, Not set

Rambam Medical Center, Haifa, Not set

Sourasky Medical Centre, Tel-Aviv, Not set

Asst Papa Giovanni Xxiii, Bergamo, Lombardia

A.O. Spedali Civili Di Brescia-P.O. Spedali Civili, Brescia, Lombardia

Yamagata University Hospital, Yamagata, Not set

Seoul National University Hospital, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Uniwersyteckie Centrum Kliniczne, Gda?sk, Not set

Pratia Onkologia Katowice, Katowice, Not set

Uniwersytecki Szpital Kliniczny w Poznaniu, Pozna?, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

University College London Hospitals NHS Foundation Trust, London, Not set

Royal Marsden Hospital, Sutton, Not set

Conditions: Multiple Myeloma

Learn More ›

Treatment of Acute Lymphoblastic Leukemia in Children

NCT00400946

Completed

RATIONALE: L-asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia, but is also associated with notable side-effects, including hypersensitivity, pancreatitis, and thrombosis. We have previously reported that patients with acute lymphoblastic leukemia in whom asparaginase treatment was discontinued because of intolerable side-effects had survival outcomes that were inferior to those who received all or nearly all of their intended doses. Two bacterial sou... Read More

Gender:

ALL

Ages:

Between 1 year and 18 years

Trial Updated:

07/08/2025

Locations: Dana Farber Cancer Institute, Boston, Massachusetts +7 locations

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia

Learn More ›

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

NCT03290950

Active Not Recruiting

This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone. The purpose of this study is to test whether giving daratumumab along with the other drugs (carfilzomib, lenalidomide and dexamethasone) is safe for patients.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations

Conditions: Multiple Myeloma

Learn More ›

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06988488

Not Yet Recruiting

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: Local Institution - 0001, Birmingham, Alabama +21 locations

Conditions: Multiple Myeloma

Learn More ›

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997

Active Not Recruiting

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: Local Institution - 035, Hot Springs, Arkansas +258 locations

Local Institution - 035, Hot Springs, Arkansas

Local Institution - 641, Cerritos, California

Local Institution - 681, Fountain Valley, California

Local Institution - 047, Los Angeles, California

Local Institution - 684, Newport, California

Local Institution - 033, New Haven, Connecticut

Local Institution - 029, Fort Myers, Florida

Local Institution - 693, Ocala, Florida

Local Institution - 028, Saint Petersburg, Florida

Local Institution - 045, Tamarac, Florida

Local Institution - 034, West Palm Beach, Florida

Local Institution - 685, Weston, Florida

Local Institution - 018, Atlanta, Georgia

Local Institution - 640, Elk Grove Village, Illinois

Local Institution - 697, Dyer, Indiana

Local Institution - 040, Louisville, Kentucky

Local Institution - 041, Alexandria, Louisiana

Local Institution - 682, Baton Rouge, Louisiana

Local Institution - 027, Baton Rouge, Louisiana

Local Institution - 698, Baltimore, Maryland

Local Institution - 014, Bethesda, Maryland

Local Institution - 688, Columbia, Maryland

Local Institution - 010, Boston, Massachusetts

Local Institution - 009, Worcester, Massachusetts

Local Institution - 645, Burnsville, Minnesota

Local Institution - 031, Kansas City, Missouri

Local Institution - 046, Billings, Montana

Local Institution - 015, Summit, New Jersey

Local Institution - 691, New York, New York

Local Institution - 039, Durham, North Carolina

Local Institution - 038, Cincinnati, Ohio

Local Institution - 037, Cleveland, Ohio

Local Institution - 008, Cleveland, Ohio

Local Institution - 036, Columbus, Ohio

Local Institution - 680, Tulsa, Oklahoma

Local Institution - 043, Portland, Oregon

Local Institution - 030, Chattanooga, Tennessee

Local Institution - 021, Nashville, Tennessee

Local Institution - 687, Austin, Texas

Local Institution - 695, Houston, Texas

Local Institution - 642, Newport News, Virginia

Local Institution - 643, Roanoke, Virginia

Local Institution - 025, Madison, Wisconsin

Local Institution - 080, Ciudad Autanoma De Buenos Aires, Buenos Aires

Local Institution - 083, Villa Elisa, Buenos Aires

Local Institution - 813, Birtinya, Queensland

Local Institution - 812, Douglas, Queensland

Local Institution - 803, Adelaide, South Australia

Local Institution - 806, Bedford Park, South Australia

Local Institution - 802, Clayton, Victoria

Local Institution - 809, East Melbourne, Victoria

Local Institution - 801, Melbourne, Victoria

Local Institution - 811, Murdoch, Western Australia

Local Institution - 807, West Perth, Western Australia

Local Institution - 804, Camperdown, Not set

Local Institution - 800, Fitzroy, Not set

Local Institution - 808, Garran, Not set

Local Institution - 155, Graz, Not set

Local Institution - 154, Linz, Not set

Local Institution - 153, Salzburg, Not set

Local Institution - 156, St Polten, Not set

Local Institution - 150, Vienna, Not set

Local Institution - 151, Wien, Not set

Local Institution - 172, Brugge, Not set

Local Institution - 174, Bruxelles, Not set

Local Institution - 056, Curitiba, Parana

Local Institution - 058, Porto Alegre, RIO Grande DO SUL

Local Institution - 050, Porto Alegre, RS

Local Institution - 054, Jau, SAO Paulo

Local Institution - 055, Sao Paulo, SP

Local Institution - 051, Barretos, São Paulo

Local Institution - 053, Rio de Janeiro, Not set

Local Institution - 057, Sao Paulo, Not set

Local Institution - 052, Sao Paulo, Not set

Local Institution - 111, Calgary, Alberta

Local Institution - 103, Edmonton, Alberta

Local Institution - 112, Surrey, British Columbia

Local Institution - 104, Saint John, New Brunswick

Local Institution - 110, St John's, Newfoundland and Labrador

Local Institution - 101, Halifax, Nova Scotia

Local Institution - 109, Ottawa, Quebec

Local Institution - 107, Saskatoon, Saskatchewan

Local Institution - 108, Quebec, Not set

Local Institution - 141, Changsha, Hunan

Local Institution - 129, Nanchang, Jiangxi

Local Institution - 143, Xian, Shaanxi

Local Institution - 142, Shanghai, Shanghai

Local Institution - 145, Taiyuan, Shanxi

Local Institution - 144, Wenzhou, Zhejiang

Local Institution - 140, Beijing, Not set

Local Institution - 139, Beijing, Not set

Local Institution - 138, Beijing, Not set

Local Institution - 126, Changchun, Not set

Local Institution - 121, Chaoyang District, Not set

Local Institution - 135, Guangzhou, Not set

Local Institution - 136, Guangzhou, Not set

Local Institution - 128, Hangzhou City, Not set

Local Institution - 120, Hangzhou, Zhejiang, Not set

Local Institution - 127, Harbin, Not set

Local Institution - 134, Nanjing, Not set

Local Institution - 132, Shanghai, Not set

Local Institution - 130, Shanghai, Not set

Local Institution - 131, Shenyang, Not set

Local Institution - 124, Suzhu, Not set

Local Institution - 133, Tianjin, Not set

Local Institution - 137, Wuhan, Not set

Local Institution - 125, Xian, Not set

Local Institution - 123, Zhengzhou, Not set

Local Institution - 601, Brno, Not set

Local Institution - 600, Ostrava-Poruba, Not set

Local Institution - 602, Prague 2, Not set

Local Institution - 371, Aalborg, Not set

Local Institution - 370, Odense, Not set

Local Institution - 372, Roskilde, Not set

Local Institution - 231, Turku, Varsinais-Suomi

Local Institution - 230, Helsinki, Not set

Local Institution - 232, Oulu, Not set

Local Institution - 463, Argenteuil, Not set

Local Institution - 462, La Roche -Sur-Yon - Cedex 9, Not set

Local Institution - 451, Lille Cedex, Not set

Local Institution - 458, Nancy Cedex, Not set

Local Institution - 454, Nantes, Not set

Local Institution - 452, Paris Cedex, Not set

Local Institution - 456, Paris, Not set

Local Institution - 464, Pessac, Not set

Local Institution - 465, Rouen, Not set

Local Institution - 457, Toulouse Cedex 9, Not set

Local Institution - 308, Kiel, Schleswig-Holstein

Local Institution - 301, Frankfurt am Main, Not set

Local Institution - 300, Hamburg, Not set

Local Institution - 302, Hamburg, Not set

Local Institution - 305, Heidelberg, Not set

Local Institution - 304, Lubeck, Not set

Local Institution - 573, Patras, Achaea

Local Institution - 574, Patra, Achaia

Local Institution - 571, Athens, Not set

Local Institution - 572, Thessaloniki, Not set

Local Institution - 570, Thessaloniki, Not set

Local Institution - 932, Hyderabad, Andhra Pradesh

Local Institution - 930, Bangalore, Karnataka

Local Institution - 934, Ernakulam, Kerala

Local Institution - 933, Mumbai, Maharashtra

Local Institution - 935, Kolkata, West Bengal

Local Institution - 931, Pondicherry, Not set

Local Institution - 752, Cork, Not set

Local Institution - 750, Dublin 9, Not set

Local Institution - 751, Galway, Not set

Local Institution - 874, Afula, HaZafon

Local Institution - 872, Haifa, Not set

Local Institution - 871, Jerusalem, Not set

Local Institution - 870, Tel Aviv, Not set

Local Institution - 873, Tel Hashomer, Not set

Local Institution - 415, Roma, Lazio

Local Institution - 400, Bologna, Not set

Local Institution - 408, Catania, Not set

Local Institution - 414, Genova, Not set

Local Institution - 404, Milano, Not set

Local Institution - 410, Novara, Not set

Local Institution - 412, Pavia, Not set

Local Institution - 402, Pisa, Not set

Local Institution - 405, Reggio Calabria, Not set

Local Institution - 401, Roma, Not set

Local Institution - 403, San Giovanni Rotondo FG, Not set

Local Institution - 406, Udine, Not set

Local Institution - 900, Matsuyama, Ehime

Local Institution - 917, Higashi-Ibaraki-gun, Ibaraki

Local Institution - 919, Shimotsuga, Tochigi

Local Institution - 920, Nerima-ku, Tokyo

Local Institution - 918, Shinagawa-ku, Tokyo

Local Institution - 915, Chuo-shi, Yamanashi

Local Institution - 912, Aomori, Not set

Local Institution - 916, Chiba, Not set

Local Institution - 911, Fukuoka, Not set

Local Institution - 903, Kamogawa, Not set

Local Institution - 902, Kyoto-City, Not set

Local Institution - 910, Nagoya, Not set

Local Institution - 901, Nagoya, Not set

Local Institution - 905, Okayama, Not set

Local Institution - 908, Osaka-Sayama, Not set

Local Institution - 907, Osaka, Not set

Local Institution - 913, Sapporo, Not set

Local Institution - 914, Sendai, Not set

Local Institution - 906, Shibuya-ku, Not set

Local Institution - 909, Shinagawa-ku, Tokyo, Not set

Local Institution - 904, Toyohashi, Not set

Local Institution - 974, Daegu, Not set

Local Institution - 973, Gyeonggi-do, Not set

Local Institution - 975, Hwasun-gun, Not set

Local Institution - 971, Seoul, Not set

Local Institution - 976, Seoul, Not set

Local Institution - 972, Seoul, Not set

Local Institution - 970, Seoul, Not set

Local Institution - 977, Seoul, Not set

Local Institution - 183, Guadalajara, Jalisco

Local Institution - 351, Dordrecht, Zuid-Holland

Local Institution - 354, Amsterdam, Not set

Local Institution - 352, Den Haag, Not set

Local Institution - 202, Bergen, Not set

Local Institution - 200, Oslo, Not set

Local Institution - 201, Trondheim, Not set

Local Institution - 631, Bialystok, Podlaskie

Local Institution - 633, Krakow, Not set

Local Institution - 635, Nowy Sacz, Not set

Local Institution - 634, Poznan, Not set

Local Institution - 636, Walbrzych, Not set

Local Institution - 630, Warszawa, Not set

Local Institution - 545, Coimbra, Not set

Local Institution - 543, Lisboa, Not set

Local Institution - 544, Lisboa, Not set

Local Institution - 540, Porto, Not set

Local Institution - 541, Porto, Not set

Local Institution - 514, Pamplona, Navarra

Local Institution - 505, Barcelona, Not set

Local Institution - 502, Barcelona, Not set

Local Institution - 511, Barcelona, Not set

Local Institution - 501, Caceres, Not set

Local Institution - 509, Cordoba, Not set

Local Institution - 510, Madrid, Not set

Local Institution - 516, Madrid, Not set

Local Institution - 504, Madrid, Not set

Local Institution - 513, Madrid, Not set

Local Institution - 503, Malaga, Not set

Local Institution - 508, Murcia, Not set

Local Institution - 506, Oviedo, Not set

Local Institution - 515, Salamanca, Not set

Local Institution - 500, Santiago de Compostela, Not set

Local Institution - 512, Valencia, Not set

Local Institution - 507, Zaragoza, Not set

Local Institution - 272, Boras, Not set

Local Institution - 271, Helsingborg, Not set

Local Institution - 851, Chur, Not set

Local Institution - 850, St. Gallen, Not set

Local Institution - 955, Niao-Sung Hsiang Kaohsiung County, Not set

Local Institution - 952, Taichung City, Not set

Local Institution - 954, Taichung, Not set

Local Institution - 951, Tainan, Taiana, Not set

Local Institution - 956, Taipei, Zhongzheng Dist., Not set

Local Institution - 950, Taipei, Not set

Local Institution - 953, Taoyuan City, Not set

Local Institution - 778, Kavaklıdere, Ankara

Local Institution - 776, Yenimahalle, Ankara

Local Institution - 777, Pendik, Istanbul

Local Institution - 771, Balçova, Izmir

Local Institution - 775, Bornova, Izmir

Local Institution - 773, Samsun, Kurupelit

Local Institution - 770, Ankara, Not set

Local Institution - 772, Gaziantep, Not set

Local Institution - 774, Kayseri, Not set

Local Institution - 702, Nottingham, Nottinghamshire

Local Institution - 705, Belfast Northern Ireland, Not set

Local Institution - 700, Birmingham, Not set

Local Institution - 707, Canterbury Kent, Not set

Local Institution - 704, Lancashire Blackpool, Not set

Local Institution - 701, London, Not set

Local Institution - 709, London, Not set

Local Institution - 706, Oxford, Not set

Local Institution - 711, Portsmouth, Not set

Local Institution - 713, Sutton, Not set

Local Institution - 708, Wolverhampton, Not set

Conditions: Multiple Myeloma

Learn More ›

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

NCT05651932

Recruiting

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco, California +20 locations

UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco, California

Mayo Clinic Hospital - Florida, Jacksonville, Florida

The Winship Cancer Institute of Emory University, Atlanta, Georgia

Massachusetts General Hospital, Boston, Massachusetts

Mayo Clinic - Transplant Center - Rochester, Rochester, Minnesota

Hackensack University Medical Center, Hackensack, New Jersey

Memorial Sloan-Kettering Cancer Center, New York, New York

Atrium Health, Levine Cancer Institute, Charlotte, North Carolina

Duke University Hospital, Durham, North Carolina

University of Pennsylvania, Philadelphia, Pennsylvania

Tennessee Oncology, Nashville, Tennessee

University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas

University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital), Toronto, Ontario

Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu, Nantes, Not set

Centre Hospitalier Universitaire de Poitiers (CHU de Poitiers), Poitiers, Not set

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, Not set

Universitaire de Lille, Villeneuve-d'Ascq, Not set

Clínica Universidad de Navarra, Pamplona, Navarra

Hospital ClÃ-nic de Barcelona, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Instituto de Investigacion Biomedica de Salamanca (IBSAL), Salamanca, Not set

Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple

Learn More ›

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

NCT05911321

Active Not Recruiting

This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that has returned or has not responded to prior treatment. The study will specifically investigate the impact of administering lower-than-standard doses of pomalidomide and dexamethasone. Using lower doses of pomalidomide and dexamethasone in this setting h... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/06/2025

Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina +1 locations

Conditions: Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity

Learn More ›

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624

Active Not Recruiting

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) and to radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria In Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) in participants with mCRPC previously treate... Read More

Gender:

ALL

Ages:

All

Trial Updated:

07/03/2025

Locations: University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange, California +278 locations

University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange, California

Stanford Cancer Center ( Site 0036), Palo Alto, California

Kaiser Permanente Riverside Medical Center ( Site 0099), Riverside, California

Anschutz Cancer Pavilion ( Site 0046), Aurora, Colorado

University of Colorado Health - Highlands Ranch Hospital ( Site 0111), Highlands Ranch, Colorado

Colorado Clinical Research ( Site 0067), Lakewood, Colorado

University of Colorado Health - Lone Tree Medical Center ( Site 0112), Lone Tree, Colorado

Yale-New Haven Hospital-Yale Cancer Center ( Site 0064), New Haven, Connecticut

Florida Cancer Specialists - South ( Site 7003), Fort Myers, Florida

Bruce W. Carter Veterans Affairs Medical Center ( Site 0082), Miami, Florida

University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051), Miami, Florida

University of Illinois at Chicago ( Site 0105), Chicago, Illinois

University of Chicago Medical Center ( Site 0045), Chicago, Illinois

University of Iowa ( Site 0047), Iowa City, Iowa

University of Kentucky Chandler Medical Center ( Site 0048), Lexington, Kentucky

Ochsner Clinic Foundation ( Site 0108), New Orleans, Louisiana

Baltimore Veterans Affairs Medical Center ( Site 0069), Baltimore, Maryland

Greenebaum Comprehensive Cancer Center ( Site 0049), Baltimore, Maryland

Henry Ford Hospital ( Site 0015), Detroit, Michigan

M Health Fairview Clinics and Surgery Center ( Site 0019), Minneapolis, Minnesota

Metro-Minnesota Community Clinical Oncology ( Site 0014), Saint Louis Park, Minnesota

Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062), Saint Louis, Missouri

University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095), Omaha, Nebraska

Comprehensive Cancer Centers of Nevada ( Site 0010), Las Vegas, Nevada

Atlantic Health System Morristown Medical Center ( Site 0115), Morristown, New Jersey

Rutgers Cancer Institute of New Jersey ( Site 0033), New Brunswick, New Jersey

James J. Peters VA Medical Center ( Site 0088), Bronx, New York

University Hospitals Cleveland Medical Center ( Site 0043), Cleveland, Ohio

Oregon Health and Science University ( Site 0028), Portland, Oregon

VA Portland Health Care System ( Site 0058), Portland, Oregon

AHN Allegheny General Hospital ( Site 0001), Pittsburgh, Pennsylvania

Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083), Charleston, South Carolina

Avera Cancer Institute - Pierre ( Site 0118), Pierre, South Dakota

Avera Cancer Institute- Research ( Site 0094), Sioux Falls, South Dakota

Avera Cancer Institute - Yankton ( Site 0117), Yankton, South Dakota

SCRI Oncology Partners ( Site 7000), Nashville, Tennessee

Texas Oncology - Central/South Texas ( Site 8003), Austin, Texas

Texas Oncology - DFW ( Site 8001), Dallas, Texas

Texas Oncology - Gulf Coast ( Site 8002), The Woodlands, Texas

University of Virginia Health System ( Site 0054), Charlottesville, Virginia

VCU Health Adult Outpatient Pavillion ( Site 0061), Richmond, Virginia

Blue Ridge Cancer Care ( Site 0004), Roanoke, Virginia

Fred Hutchinson Cancer Center ( Site 0013), Seattle, Washington

MEDICAL COLLEGE OF WISCONSIN ( Site 0020), Milwaukee, Wisconsin

Hospital Británico de Buenos Aires-Oncology ( Site 0202), Ciudad autónoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201), Mar del Plata, Buenos Aires

Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205), Buenos Aires, Caba

Instituto Alexander Fleming-Alexander Fleming ( Site 0206), Ciudad Autónoma de Buenos Aires, Caba

Sanatorio Parque ( Site 0208), Rosario, Santa Fe

Hospital Aleman-Oncology ( Site 0207), Buenos Aires, Not set

Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0204), Mendoza, Not set

Dubbo Hospital ( Site 0235), Dubbo, New South Wales

Macquarie University-MQ Health Clinical Trials Unit ( Site 0234), Macquarie University, New South Wales

Westmead Hospital ( Site 0232), Westmead, New South Wales

Princess Alexandra Hospital-Cancer Care Serices ( Site 0237), Brisbane, Queensland

Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0230), Melbourne, Victoria

Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0276), Linz, Oberosterreich

Klinikum Wels-Grieskirchen GmbH ( Site 0279), Wels, Oberosterreich

Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0280), Graz, Steiermark

Obras Sociais Irma Dulce ( Site 0302), Salvador, Bahia

Hospital Santa Rita de Cassia-Centro de Pesquisa Clínica ( Site 0320), Vitoria, Espirito Santo

Hospital Felicio Rocho ( Site 0317), Belo Horizonte, Minas Gerais

Hospital Mario Penna ( Site 0309), Belo Horizonte, Minas Gerais

Hospital Universitário Evangélico Mackenzie-Centro de Oncologia Mackenzie ( Site 0314), Curitiba, Parana

Clínica de Neoplasias Litoral ( Site 0305), Itajai, Santa Catarina

Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0308), Bragança Paulista, Sao Paulo

A. C. Camargo Cancer Center ( Site 0310), São Paulo, Sao Paulo

Cross Cancer Institute ( Site 0332), Edmonton, Alberta

The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0336), Ottawa, Ontario

Sunnybrook Research Institute ( Site 0331), Toronto, Ontario

Princess Margaret Cancer Centre ( Site 0330), Toronto, Ontario

Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0328), Greenfield Park, Quebec

Centre Hospitalier de l'Université de Montréal ( Site 0326), Montréal, Quebec

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0327), Quebec City, Quebec

Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0329), Sherbrooke, Quebec

IC La Serena Research ( Site 0356), La Serena., Coquimbo

Clinical Research Chile SpA ( Site 0358), Valdivia, Los Rios

Clinica Universidad Catolica del Maule-Oncology ( Site 0355), Talca, Maule

FALP ( Site 0353), Santiago, Region M. De Santiago

Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0354), Santiago, Region M. De Santiago

Bradfordhill-Clinical Area ( Site 0351), Santiago, Region M. De Santiago

Bradford Hill Norte ( Site 0357), Antofagasta, Not set

Second Affiliated hospital of Anhui Medical University-Urology ( Site 0408), Hefei, Anhui

Peking University First Hospital-Urology ( Site 0390), Beijing, Beijing

Beijing Friendship Hospital Affiliate of Capital University ( Site 0396), Beijing, Beijing

Beijing Cancer hospital-Urinary Surgery ( Site 0395), Beijing, Beijing

The First Affiliated Hospital of Chongqing Medical University ( Site 0427), Chongqing, Chongqing

Chongqing University Cancer Hospital ( Site 0416), Chongqing, Chongqing

Southwest Hospital of Third Military Medical University ( Site 0420), Chongqing, Chongqing

Chongqing Three Gorges Central Hospital's ( Site 0426), Chongqing, Chongqing

The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0414), Fuzhou, Fujian

The First Affiliated hospital of Xiamen University-Urology ( Site 0415), Xiamen, Fujian

The First Affiliated Hospital of Guangzhou Medical University ( Site 0412), Guangzhou, Guangdong

Sun Yat-sen University Cancer Center-Internal medicine ( Site 0413), Guangzhou, Guangdong

Tongji Hospital Tongji Medical,Science & Technology ( Site 0407), Wuhan, Hubei

Hubei Cancer Hospital-Urinary surgery ( Site 0406), Wuhan, Hubei

Hunan Cancer Hospital ( Site 0405), Changsha, Hunan

First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0436), Huaian, Jiangsu

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 0377), NanJing, Jiangsu

Affiliated hospital of Jiangnan university ( Site 0434), Wuxi, Jiangsu

Jiangxi Cancer Hospital ( Site 0386), Nanchang, Jiangxi

The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 0394), XI An, Shaanxi

The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 0393), Xi'an, Shaanxi

Yantai Yuhuangding Hospital ( Site 0397), Yantai, Shandong

Fudan University Shanghai Cancer Center-Urology department ( Site 0376), Shanghai, Shanghai

Huadong Hospital Affiliated to Fudan University-Urology ( Site 0388), Shanghai, Shanghai

West China Hospital, Sichuan University-Urology Surgery ( Site 0417), Cheng Du, Sichuan

The Third People's Hospital of Chengdu (CDTPH) ( Site 0428), Chengdu, Sichuan

Nanchong Central Hospital-urology ( Site 0422), Nanchong, Sichuan

Suining Central Hospital ( Site 0437), Suining, Sichuan

Tianjin Medical University Cancer Institute & Hospital ( Site 0392), Tianjin, Tianjin

The Second Hospital of Tianjin Medical University ( Site 0391), Tianjin, Tianjin

Xinjiang Medical University Cancer Hospital - Urumqi-Urology ( Site 0419), Urumqi, Xinjiang

The Second Affiliated Hospital Of Kunming Medical University ( Site 0429), Kunming, Yunnan

Yunnan Province Cancer Hospital ( Site 0418), Kunming, Yunnan

Zhejiang Provincial People's Hospital-Urology ( Site 0378), Hangzhou, Zhejiang

Zhejiang Cancer Hospital ( Site 0435), Hangzhou, Zhejiang

The First Hospital of Jiaxing-urology ( Site 0380), Jiaxing, Zhejiang

The First Affiliated Hospital of Ningbo University ( Site 0383), Ningbo, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 0379), Wenzhou, Zhejiang

Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0502), Valledupar, Cesar

IMAT S.A.S ( Site 0504), Monteria, Cordoba

Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0501), Bogota, Distrito Capital De Bogota

Fundación Cardiovascular de Colombia ( Site 0503), Piedecuesta, Santander

Fundación Valle del Lili ( Site 0505), Cali, Valle Del Cauca

Clínica Imbanaco S.A.S ( Site 0509), Cali, Valle Del Cauca

Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0553), Brno, Brno-mesto

Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0554), Ostrava, Moravskoslezsky Kraj

Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0555), Olomouc, Olomoucky Kraj

Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551), Praha, Praha 5

Rigshospitalet ( Site 0576), Copenhagen, Hovedstaden

Odense Universitetshospital-Department of oncology ( Site 0579), Odense, Syddanmark

Vejle Sygehus ( Site 0578), Vejle, Syddanmark

Tampereen yliopistollinen sairaala ( Site 0604), Tampere, Pirkanmaa

Kuopion Yliopistollinen Sairaala ( Site 0603), Kuopio, Pohjois-Savo

Turku University Hospital-Department of Oncology ( Site 0601), Turku, Varsinais-Suomi

Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0627), Strasbourg, Alsace

Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire ( Site 0630), Nîmes, Gard

Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0632), Rennes, Ille-et-Vilaine

Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 0629), Clermont-Ferrand, Puy-de-Dome

Centre Hospitalier de la Côte Basque ( Site 0633), Bayonne, Pyrenees-Atlantiques

Gustave Roussy ( Site 0626), Villejuif, Val-de-Marne

Hôpital Européen Georges Pompidou ( Site 0628), Paris, Not set

klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0696), Munich, Bayern

HELIOS Kliniken Schwerin ( Site 0694), Schwerin, Mecklenburg-Vorpommern

Universitätsklinikum Bonn-Klinik und Poliklinik für Urologie und Kinderurologie ( Site 0680), Bonn, Nordrhein-Westfalen

Universitätsklinikum Münster - Albert Schweitzer Campus-Klinik für Urologie ( Site 0678), Münster, Nordrhein-Westfalen

Universitätsklinikum Schleswig-Holstein-Klinik für Urologie ( Site 0691), Lubeck, Schleswig-Holstein

Universitätsklinikum Jena-Klinik und Poliklinik für Urologie ( Site 0682), Jena, Thuringen

Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0679), Berlin, Not set

Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0705), Hamburg, Not set

Queen Mary Hospital ( Site 0727), Hong Kong, Not set

Prince of Wales Hospital ( Site 0730), Shatin, Not set

Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 0752), Kecskemét, Bacs-Kiskun

Nograd Varmegyei Szent Lazar Korhaz-Onkologia es Sugarterapias Osztaly ( Site 0761), Salgótarján, Nograd

Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 0756), Budapest, Pest

Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0758), Debrecen, Not set

St. Vincent's University Hospital ( Site 0802), Dublin 04, Dublin

Tallaght University Hospital ( Site 0801), Dublin, Not set

Emek Medical Center ( Site 0830), Afula, Not set

Rambam Health Care Campus-Oncology Division ( Site 0826), Haifa, Not set

Hadassah Medical Center ( Site 0833), Jerusalem, Not set

Meir Medical Center. ( Site 0832), Kfar Saba, Not set

Rabin Medical Center ( Site 0828), Petah Tikva, Not set

Sheba Medical Center ( Site 0827), Ramat Gan, Not set

IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 0879), Meldola, Emilia-Romagna

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0877), Milan, Lombardia

Ospedale San Raffaele-Oncologia Medica ( Site 0876), Milano, Not set

Toho University Sakura Medical Center ( Site 0906), Sakura, Chiba

Ehime University Hospital ( Site 0918), Toon, Ehime

Hospital of the University of Occupational and Environmental Health, Japan ( Site 0921), Kitakyushu, Fukuoka

Kurume University Hospital ( Site 0920), Kurume, Fukuoka

Asahikawa Medical University Hospital ( Site 0901), Asahikawa, Hokkaido

Sapporo Medical University Hospital ( Site 0902), Sapporo, Hokkaido

Hokkaido University Hospital ( Site 0931), Sapporo, Hokkaido

Kobe University Hospital ( Site 0914), Kobe, Hyogo

Kanazawa Medical University Hospital ( Site 0909), Uchinada, Ishikawa

Kagawa University Hospital ( Site 0917), Kita, Kagawa

Yokohama City University Medical Center ( Site 0908), Yokohama, Kanagawa

National Hospital Organization Nagasaki Medical Center ( Site 0923), Ōmura, Nagasaki

Nara Medical University Hospital ( Site 0915), Kashihara, Nara

Nanbu Tokushukai Hospital ( Site 0930), Shimajiri, Okinawa

Kansai Medical University Hospital ( Site 0912), Hirakata, Osaka

Bell Land General Hospital ( Site 0913), Sakai, Osaka

The University of Osaka Hospital ( Site 0911), Suita, Osaka

Saga-Ken Medical Centre Koseikan ( Site 0922), Saga-shi, Saga

The Jikei University Hospital ( Site 0907), Minato, Tokyo

Akita University Hospital ( Site 0904), Akita, Not set

Kyushu University Hospital ( Site 0919), Fukuoka, Not set

Fukushima Medical University Hospital ( Site 0933), Fukushima, Not set

Gifu University Hospital ( Site 0910), Gifu, Not set

Hiroshima University Hospital ( Site 0916), Hiroshima, Not set

Kagoshima University Hospital ( Site 0929), Kagoshima, Not set

National Hospital Organization Kumamoto Medical Center ( Site 0924), Kumamoto, Not set

Miyazaki Prefectural Miyazaki Hospital ( Site 0927), Miyazaki, Not set

University of Miyazaki Hospital ( Site 0926), Miyazaki, Not set

Nagano Municipal Hospital ( Site 0932), Nagano, Not set

National Hospital Organization Oita Medical Center ( Site 0925), Oita, Not set

Asan Medical Center-Oncology ( Site 1402), Songpagu, Seoul

Seoul National University Hospital-Oncology ( Site 1401), Seoul, Not set

Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1404), Seoul, Not set

Samsung Medical Center ( Site 1405), Seoul, Not set

Hospital Sultan Ismail ( Site 1081), Johor Bahru, Johor

University Malaya Medical Centre ( Site 1077), Lembah Pantai, Kuala Lumpur

Sarawak General Hospital-Radiotherapy Unit ( Site 1076), Kuching, Sarawak

National Cancer Institute ( Site 1079), Putrajaya, Wilayah Persekutuan Putrajaya

Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1078), Kuala Lumpur, Not set

Quemex Medical and Research ( Site 1112), Mexico City, Distrito Federal

CIO - Centro de Inmuno-Oncología de Occidente ( Site 1103), Guadalajara, Jalisco

Filios Alta Medicina ( Site 1106), Monterrey, Nuevo Leon

Medical Care and Research SA de CV ( Site 1108), Merida, Yucatan

Centro de Investigacion Clinica de Oaxaca ( Site 1109), Oaxaca, Not set

Medische Centrum Leeuwarden ( Site 1172), Leeuwarden, Fryslan

Radboudumc-Medical Oncology ( Site 1152), Nijmegen, Gelderland

Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1163), Sittard-Geleen, Limburg

VieCuri Medisch Centrum ( Site 1173), Venlo, Limburg

ETZ Elisabeth-Internal Medicine ( Site 1160), Tilburg, Noord-Brabant

Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1153), Amsterdam, Noord-Holland

Amsterdam UMC, locatie VUmc ( Site 1156), Amsterdam, Noord-Holland

Spaarne Gasthuis - Hoofddorp-Oncology ( Site 1170), Hoofddorp, Noord-Holland

Meander Medisch Centrum ( Site 1157), Amersfoort, Utrecht

Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1164), Den Haag, Zuid-Holland

Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1151), Schiedam, Zuid-Holland

Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1201), Tauranga, Bay Of Plenty

Dunedin Hospital-Southern Blood and Cancers Service ( Site 1203), Dunedin, Otago

Akershus Universitetssykehus-Onkologisk avdeling ( Site 1227), Lørenskog, Akershus

Sykehuset Østfold Kalnes ( Site 1228), Sarpsborg, Ostfold

St. Olavs Hospital-Kreftklinikken ( Site 1231), Trondheim, Sor-Trondelag

Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 1258), Concepcion, Junin

Clínica Sánchez Ferrer ( Site 1261), Trujillo, La Libertad

Aliada-Oncologìa ( Site 1257), Lima, Not set

IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 1254), Lima, Not set

Oncosalud-Clinical Research ( Site 1260), Lima, Not set

INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 1256), Lima, Not set

Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1302), Bydgoszcz, Kujawsko-pomorskie

Regionalny Szpital Specjalistyczny im. dr. Władyslawa Biegańskiego ( Site 1316), Grudziadz, Kujawsko-pomorskie

Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 1304), Torun, Kujawsko-pomorskie

Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1310), Siedlce, Mazowieckie

Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 1318), Kielce, Swietokrzyskie

Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1303), Koszalin, Zachodniopomorskie

Zachodniopomorskie Centrum Onkologii ( Site 1311), Szczecin, Zachodniopomorskie

Puerto Rico Medical Research Center LLC ( Site 1354), Hato Rey, Not set

Ad-Vance Medical Research-Research ( Site 1353), Ponce, Not set

Pan American Center for Oncology Trials - Ciudadela ( Site 1351), San Juan, Not set

National University Hospital ( Site 1376), Singapore, Central Singapore

National Cancer Centre Singapore ( Site 1377), Singapore, Central Singapore

Tan Tock Seng Hospital-Medical Oncology ( Site 1378), Singapore, Central Singapore

Hospital Jerez de la Frontera ( Site 1427), Jerez de la Frontera, Cadiz

Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1431), Madrid, Madrid, Comunidad De

Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1433), Madrid, Madrid, Comunidad De

Complexo Hospitalario Universitario de Ourense ( Site 1426), Ourense, Orense

Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1430), Valencia, Valenciana, Comunitat

Hospital Lucus Augusti-Oncology ( Site 1432), Lugo, Not set

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 1428), Sevilla, Not set

Karolinska Universitetssjukhuset Solna ( Site 1478), Stockholm, Stockholms Lan

Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1477), Uppsala, Uppsala Lan

Sahlgrenska Universitetssjukhuset ( Site 1479), Gothenburg, Vastra Gotalands Lan

China Medical University Hospital-Department of Urology ( Site 1503), Taichung, Not set

National Cheng Kung University Hospital-Urology ( Site 1502), Tainan, Not set

National Taiwan University Hospital-Urology ( Site 1506), Taipei, Not set

Taipei Veterans General Hospital ( Site 1505), Taipei, Not set

Chang Gung Medical Foundation-Linkou Branch-Medical Oncology ( Site 1504), Taoyuan, Not set

Faculty of Medicine - Khon Kaen University ( Site 1526), Muang, Khon Kaen

Chulalongkorn University ( Site 1530), Bangkok, Krung Thep Maha Nakhon

Faculty of Medicine Siriraj Hospital ( Site 1531), Bangkok, Krung Thep Maha Nakhon

Songklanagarind hospital ( Site 1527), Hatyai, Songkhla

Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1554), Adana, Not set

Gulhane Egitim Arastirma Hastanesi ( Site 1558), Ankara, Not set

Hacettepe Universite Hastaneleri-oncology hospital ( Site 1551), Ankara, Not set

Memorial Ankara Hastanesi-Medical Oncology ( Site 1557), Ankara, Not set

Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1552), Ankara, Not set

Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1555), Istanbul, Not set

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1553), Istanbul, Not set

Addenbrooke's Hospital ( Site 1605), Cambridge, Cambridgeshire

The Royal Cornwall Hospital ( Site 1610), Truro, England

The Beatson West of Scotland Cancer Centre ( Site 1603), Glasgow, Glasgow City

Charing Cross Hospital-Oncology Research ( Site 1606), London, Hammersmith And Fulham

University College London Hospital ( Site 1612), London, London, City Of

The Christie NHS Foundation Trust ( Site 1608), Manchester, Not set

Conditions: Prostate Cancer Metastatic

Learn More ›

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

NCT05451771

Recruiting

The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/03/2025

Locations: Boston Medical Center, Boston, Massachusetts +3 locations

Conditions: AL Amyloidosis

Learn More ›

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

NCT01745588

Active Not Recruiting

The purpose of this study is to see whether pomalidomide (also known as Pomalyst) reduces the number of myeloma cells in the bones, and to see what is the best way to use pomalidomide in patients with myeloma. To do this, the investigators want to compare two types of treatment using pomalidomde. This is a randomized trial which means that the decision as to which treatment the patient will receive will be made by a computer, much like flipping a coin. All patients start by receiving 4 cycles o... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/02/2025

Locations: Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey +9 locations

Conditions: Multiple Myeloma

Learn More ›

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT

NCT04862468

Recruiting

This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for up to 14 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up... Read More

Gender:

ALL

Ages:

Between 18 years and 89 years

Trial Updated:

07/01/2025

Locations: Providence St. Joseph Hospital, Orange, California +16 locations

Conditions: Thrombosis, Deep Vein, Iliofemoral; Thrombosis

Learn More ›

Browse by State

Dexamethasone treatment options in Alabama

Dexamethasone treatment options in Alaska

Dexamethasone treatment options in Arizona

Dexamethasone treatment options in Arkansas

Dexamethasone treatment options in California

Dexamethasone treatment options in Colorado

Dexamethasone treatment options in Connecticut

Dexamethasone treatment options in Delaware

Dexamethasone treatment options in District of Columbia

Dexamethasone treatment options in Florida

Dexamethasone treatment options in Georgia

Dexamethasone treatment options in Hawaii

Dexamethasone treatment options in Idaho

Dexamethasone treatment options in Illinois

Dexamethasone treatment options in Indiana

Dexamethasone treatment options in Iowa

Dexamethasone treatment options in Kansas

Dexamethasone treatment options in Kentucky

Dexamethasone treatment options in Louisiana

Dexamethasone treatment options in Maine

Dexamethasone treatment options in Montana

Dexamethasone treatment options in Nebraska

Dexamethasone treatment options in Nevada

Dexamethasone treatment options in New Hampshire

Dexamethasone treatment options in New Jersey

Dexamethasone treatment options in New Mexico

Dexamethasone treatment options in New York

Dexamethasone treatment options in North Carolina

Dexamethasone treatment options in North Dakota

Dexamethasone treatment options in Ohio

Dexamethasone treatment options in Oklahoma

Dexamethasone treatment options in Oregon

Dexamethasone treatment options in Maryland

Dexamethasone treatment options in Massachusetts

Dexamethasone treatment options in Michigan

Dexamethasone treatment options in Minnesota

Dexamethasone treatment options in Mississippi

Dexamethasone treatment options in Missouri

Dexamethasone treatment options in Pennsylvania

Dexamethasone treatment options in Rhode Island

Dexamethasone treatment options in South Carolina

Dexamethasone treatment options in South Dakota

Dexamethasone treatment options in Tennessee

Dexamethasone treatment options in Texas

Dexamethasone treatment options in Utah

Dexamethasone treatment options in Vermont

Dexamethasone treatment options in Virginia

Dexamethasone treatment options in Washington

Dexamethasone treatment options in West Virginia

Dexamethasone treatment options in Wisconsin

Dexamethasone treatment options in Wyoming